Concepedia

Ye Xu

YX

Statistics

Publications

14

Citations

746

H-Index

11

Active since

2011

Affiliations

Fudan University Shanghai Cancer Center(Current)

Central South University

Xiangya Hospital Central South University

Shanghai Medical College of Fudan University

Harbin Medical University

Ye Xu is an author at Fudan University Shanghai Cancer Center specializing in medicine, oncology, and malignant neoplasms.

ORCID

Publications per year

2011–2022

14

Publications

14

CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma

Jingyue Yao, Jubo Wang, Ye Xu et al. · Autophagy · 2021 · 258 citations · Full text

, , +14

MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling

Jia‐Quan Qu, Hongmei Yi, Ye Xu et al. · Molecular Cancer Therapeutics · 2015 · 92 citations

, , +17

MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway

Jia‐Quan Qu, Hongmei Yi, Ye Xu et al. · Oncotarget · 2015 · 63 citations · Full text

, , +16

The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4 /NF-κB signaling pathway activation in oral lichen planus

Yana Ge, Ye Xu, Wenjing Sun et al. · Gene · 2012 · 60 citations

, , +11

Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling

Jingyue Yao, Shu Xu, Yuening Sun et al. · Acta Pharmacologica Sinica · 2021 · 52 citations · Full text

, , +15

1–5 of 14